--- title: "Relmada Therapeutics (RLMD) news: offering" url: "https://aibio.space/companies/relmada-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "RLMD offering news: Relmada Therapeutics agrees to approximately $160.0 million private placement at $4.75 a share. Relmada Therapeutics, Inc." --- RLMD Relmada Therapeutics, Inc. NASDAQ · United States # Relmada Therapeutics (RLMD) news RLMD offering news Financings · 2026-03-09 ## [Relmada Therapeutics agrees to approximately $160.0 million private placement at $4.75 a share](https://aibio.space/news/relmada-therapeutics-agrees-approximately-160-0-million-private/) Relmada agreed to sell 29,474,569 shares and pre-funded warrants for up to 4,210,527 shares to institutional and accredited investors. It announced 12-month Phase 2 data for NDV-01 the same day, where the 12-month response rate rests on 25 patients. ## Latest Relmada Therapeutics news 1. 2025-09-16 Listings [Relmada Therapeutics regains compliance with Nasdaq $1.00 bid price rule](https://aibio.space/news/relmada-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/) Relmada Therapeutics said on September 16, 2025 that Nasdaq confirmed in a September 15 notice that it has regained compliance with the $1.00 minimum bid price. The stock stays on the Nasdaq Capital Market under RLMD, but the company's lead drug failed in late 2024. 2. 2025-03-26 Financings [Relmada licenses NDV-01 from Trigone, agrees to pay $3,500,000 and issue 3,017,420 shares](https://aibio.space/news/relmada-licenses-ndv-01-trigone-agrees-pay-3-500-000-issue-3-017-420/) Relmada Therapeutics agreed on March 24, 2025 to license NDV-01 from Trigone Pharma for a $3,500,000 upfront fee and 3,017,420 restricted shares, which the press release says is 10% of its outstanding stock. Milestones can reach $200 million, and from 2026 Relmada must spend at least $5,000,000 a year on the drug. ## Relmada Therapeutics at a glance - **Ticker**: RLMD - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $217.7 million ### Related companies - [Allarity Therapeutics](https://aibio.space/companies/allarity-therapeutics/) NASDAQ: ALLR - [Abeona Therapeutics](https://aibio.space/companies/abeona-therapeutics/) NASDAQ: ABEO - [Akebia Therapeutics](https://aibio.space/companies/akebia-therapeutics/) NASDAQ: AKBA - [Biomea Fusion](https://aibio.space/companies/biomea-fusion/) NASDAQ: BMEA - [TRex Bio](https://aibio.space/companies/trex-bio/) NASDAQ: TRXB - [NextCure](https://aibio.space/companies/nextcure/) NASDAQ: NXTC - [Avalyn Pharma](https://aibio.space/companies/avalyn-pharma/) NASDAQ: AVLN - [CNS Pharmaceuticals](https://aibio.space/companies/cns-pharmaceuticals/) NASDAQ: CNSP ### Also on NASDAQ - [Atossa Therapeutics](https://aibio.space/companies/atossa-therapeutics/) ATOS - [TransCode Therapeutics](https://aibio.space/companies/transcode-therapeutics/) RNAZ - [Larimar Therapeutics](https://aibio.space/companies/larimar-therapeutics/) LRMR - [KESTRA MEDICAL TECHNOLOGIES, LTD.](https://aibio.space/companies/kestra-medical-technologies/) KMTS - [Embecta](https://aibio.space/companies/embecta/) EMBC - [NEUROONE MEDICAL TECHNOLOGIES](https://aibio.space/companies/neuroone-medical-technologies/) NMTC ## What Relmada Therapeutics does Relmada Therapeutics, Inc. is a publicly traded, clinical-stage biotechnology company. After a strategic review in late 2024 and early 2025, it terminated esmethadone (REL-1017) and its REL-P11 psilocybin program, and it acquired new development candidates instead. Its lead product, NDV-01, is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel that it in-licensed from Trigone Pharma Ltd. NDV-01 is in a Phase 2 clinical trial in Israel for aggressive forms of non muscle-invasive bladder cancer (NMIBC). The company intends to develop NDV-01 for high-risk, 2nd line BCG-unresponsive NMIBC and for intermediate risk patients in the adjuvant setting, and expects to start Phase 3 programs for both indications in mid-2026. Its second product, sepranolone, is a neurosteroid epimer of allopregnanolone acquired from Asarina Pharma AB. It is being developed for Prader-Willi syndrome (PWS), Tourette Syndrome (TS), essential tremor and other diseases related to excessive GABAergic activity, with a Phase 2 study in PWS expected to start in mid-2026. The company also reports that FDA agreed to key elements of the planned NDV-01 Phase 3 program. | Product or program | What it is | Stage | |---|---|---| | NDV-01 | Controlled-release intravesical gemcitabine and docetaxel for NMIBC | Phase 2 | | Sepranolone | Neurosteroid epimer of allopregnanolone for PWS, TS, essential tremor and related diseases | Phase 2b-ready | Summarised from the company's [10-K filed Mar 19, 2026](https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/ea0273255-10k_relmada.htm). ## Relmada Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$26.9 million](https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/) | [$46.2 million](https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/) | | Net income (loss) | [-$57.4 million](https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/) | [-$80.0 million](https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/) | | Cash from operations | [-$45.8 million](https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/) | [-$51.8 million](https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/) | | Cash and equivalents | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1553643/000121390026086151/) | [$3.9 million](https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/) | | Short-term investments | [$89.5 million](https://www.sec.gov/Archives/edgar/data/1553643/000121390026086151/) | [$41.1 million](https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $11.3 million, plus short-term investments of $206.4 million, $217.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Relmada Therapeutics Has Relmada Therapeutics raised money recently? Our latest story on this, dated Mar 9, 2026: "Relmada Therapeutics agrees to approximately $160.0 million private placement at $4.75 a share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/relmada-therapeutics-agrees-approximately-160-0-million-private/). What is the ticker symbol of Relmada Therapeutics? Relmada Therapeutics, Inc. trades under the ticker RLMD on NASDAQ. Where is Relmada Therapeutics listed? Relmada Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:4E2. What is the SEC CIK of Relmada Therapeutics? The SEC Central Index Key (CIK) for Relmada Therapeutics, Inc. is 1553643. Its filings are on SEC EDGAR. How many shares does Relmada Therapeutics have outstanding? 106,669,846 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Relmada Therapeutics listed under? Our directory records Relmada Therapeutics, Inc. under United States. What does Relmada Therapeutics do? Our directory classifies Relmada Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Relmada Therapeutics? The ISIN recorded for Relmada Therapeutics, Inc. is US75955J4022. Does aibio.space cover Relmada Therapeutics? aibio.space lists Relmada Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Relmada Therapeutics incorporated? SEC records list its state or country of incorporation as NV. What does Relmada Therapeutics develop? Relmada Therapeutics, Inc. is a publicly traded, clinical-stage biotechnology company. After a strategic review in late 2024 and early 2025, it terminated esmethadone (REL-1017) and its REL-P11 psilocybin program, and it acquired new development candidates instead. What is NDV-01 from Relmada Therapeutics? NDV-01: Controlled-release intravesical gemcitabine and docetaxel for NMIBC Stage: Phase 2. What is Sepranolone from Relmada Therapeutics? Sepranolone: Neurosteroid epimer of allopregnanolone for PWS, TS, essential tremor and related diseases Stage: Phase 2b-ready. Is Relmada Therapeutics profitable? Relmada Therapeutics, Inc. reported a net loss of $57.4 million for the fiscal year ended Dec 31, 2025, and used $45.8 million of cash in operations, per its annual report to the SEC. How much does Relmada Therapeutics spend on research and development? $26.9 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Relmada Therapeutics Members talk about Relmada Therapeutics (RLMD). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Relmada Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-05-28 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1553643/000121390026062184/ea0292521-8k_relmada.htm) 2. 2026-05-13 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1553643/000121390026055901/ea0290172-s3asr_relmada.htm) 3. 2026-03-19 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/ea0273255-10k_relmada.htm) 4. 2026-03-09 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1553643/000121390026024918/ea028043601ex99-1.htm) 5. 2026-01-30 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1553643/000121390026010313/ea0274727-424b5_relmada.htm) 6. 2025-11-05 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1553643/000121390025106396/ea0263307-424b5_relmada.htm) 7. 2025-09-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1553643/000121390025087926/ea025749701ex99-1_relmada.htm) 8. 2025-07-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1553643/000121390025066995/ea0249919-8k_relmada.htm) 9. 2025-07-10 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1553643/000121390025062803/ea0248503-8k_relmada.htm) 10. 2025-05-12 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1553643/000121390025042024/ea024173301-8k_relmada.htm) 11. 2025-04-28 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1553643/000121390025035961/ea0239654-424b5_relmada.htm) 12. 2025-03-27 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1553643/000101376225003426/ea0229064-10k_relmada.htm) 13. 2025-03-26 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1553643/000101376225002786/ea023568101ex99-1_relmada.htm) 14. 2025-01-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1553643/000121390025006727/ea0228747-8k_relmada.htm) 15. 2024-12-09 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1553643/000121390024106646/ea022402601ex99-1_relmada.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RLMD on TradingView](https://www.tradingview.com/symbols/NASDAQ-RLMD/). ## SEC filings and registration - **SEC name**: Relmada Therapeutics, Inc. - **CIK**: 1553643 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: RLMD (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, FL, 33134 - **Phone**: 646 876 3459 - **Shares outstanding**: 106,669,846 as of 2026-08-04 (10-Q filed 2026-08-06) - **Former names**: CAMP NINE, INC. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1553643/000121390026097851/ea0304768-8k_relmada.htm) filed 2026-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1553643/000121390026086190/ea0300993-8k_relmada.htm) filed 2026-08-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1553643/000121390026086151/ea0298199-10q_relmada.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1553643/000121390026082007/ea0299449-8k_relmada.htm) filed 2026-07-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1553643/000121390026062184/ea0292521-8k_relmada.htm) filed 2026-05-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1553643/000121390026055164/ea0290414-8k_relmada.htm) filed 2026-05-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1553643/000121390026055059/ea0285987-10q_relmada.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1553643/000121390026045192/ea0273288-03.htm) filed 2026-04-17 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001553643), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Relmada Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RLMD, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Relmada Therapeutics, Inc. - **Ticker**: RLMD - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US75955J4022 - **Other listed symbols**: GETTEX:4E2 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RLMD/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/relmada-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Relmada Therapeutics (RLMD) news: offering", 2026-10-31, https://aibio.space/companies/relmada-therapeutics/